Oscotec's SYK Inhibitor Program Gets Korea Drug Fund Money
This article was originally published in PharmAsia News
Oscotec is set to accelerate the development of a novel oral rheumatoid arthritis drug, helped by financial support from the state-run Korea Drug Development Fund for a US Phase I clinical trial of the South Korean venture’s spleen tyrosine kinase inhibitor.
You may also be interested in...
Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.